



Ludger procainamide

Christmas Orders and Delivery Information



Our offices will be closed between 25th December and 1st January.
Orders received before 15th December 2017 should be processed and delivered before Christmas.
First orders to go out in 2018 will be on 2nd January 2018.

Using Procainamide for Glycan Labelling

Procainamide labelling permits glycan identification by either mass spectrometry or (U)HPLC, and because of its improved ionisation efficiency compared to 2AB labelling it can permit identification of minor glycans (<1% relative peak area) by ESI-MS.

Ludger's procainamide labelling system is suitable for N-glycans, O-glycans, GSL-glycans, heparin or any sugar with a reducing terminus. The Table below outlines the features and benefits of Ludger's procainamide labelling technology in comparison to competitor offerings:

	Ludger Procainamide	Rapid/instant labelling*
Sensitive fluorescence detection for relative glycan quantitation by (U)HPLC	✓✓✓✓✓	✓✓✓✓✓
Sensitive ESI-MS and MS/MS detection for glycan structural analysis	✓✓✓✓✓	✓✓✓✓✓
Sample processing speed	✓✓✓	✓✓✓✓✓
Can label purified glycans and standards?	YES	NO
Use for O-glycans?	YES	NO
Use for GSL glycans?	YES	NO
Similar glycan derivatisation chemistry to 2-AB industry standard?	YES	NO
Suitable for exoglycosidase sequencing?	YES	Fluorophore dependent **

*rapid/instant labelling technologies use N-hydroxysuccinimide (NHS) activated fluorophores that react with the glycosylamine form of the glycan

**aminoquinoline labels are not compatible with Bovine Kidney Fucosidase (BKF)

Two procainamide labelling kits are available; LT-KPROC-24 and LT-KPROC-VP24.

The **LT-KPROC-24** kit contains sodium cyanoborohydride as the reductant. Sodium cyanoborohydride is highly efficient for reductive amination, producing labelled glycans in high yields.

The **LT-KPROC-VP24** kit contains 2-picoline borane (2-PB) as a reductant. 2-PB is less toxic than sodium cyanoborohydride. The yields of fully reduced labelled glycans might be lower when compared to sodium cyanoborohydride reductant.

For more information, please visit: www.ludger.com/procainamide

To request a quote, please contact us: info@ludger.com

Appointment of Chief Operating Officer

We are delighted to announce that Paul Plume will be joining Ludger in November as Chief Operating Officer. Paul's previous role was Program Director at the Getinge Group where he worked on stakeholder Group Projects spanning 6 global manufacturing sites, 3 global design centres and all group functions. Specific projects included regulatory, computer system, quality, systems delivery, product flow, branding and product safety. Prior to this Paul was at Abbott for over 12 years moving through a variety of functional areas covering capacity planning, engineering and operations for a variety of technical business units within Abbott's portfolio of devices, diagnostics and therapeutics. He has a Bachelor in Engineering from Leeds and an advanced course certificate from University of Cambridge for Design, Manufacture and Management.

Paul will add great value to Ludger as it continues on its journey.

China Seminar

Daryl Fernandes, Chief Executive recently gave a seminar to members of the Chinese Biopharmaceutical Industry. This event was an excellent opportunity for us to meet drug developers in China and to share our expertise in the field of Glycobiology. The event was held at Shanghai's Zhangjiang Hi-tech Park Conference Hall. Daryl's talk was entitled "GlyShape: a strategic technology programme for streamlining QbD-based development of glycoprotein therapeutics" and attracted much interest.

Lily Wang, Technical Sales Executive, Ludger China said "This seminar was a great success and there were many interesting technical discussions on the day". **Cindy Li, Sales Executive, Ludger China** commented "We look forward to working closely with our clients in China and helping them to achieve their goals".



Bruker Daltonics co-hosted this event and gave a talk entitled "Bruker Innovative Mass Spectrometry helps you improve the efficiency of protein drug mass spectrometry".

For more information on Ludger's GlyShape programme and how it can be implemented for biosimilar drug development please contact us: info@ludger.com

Quantitative Xylose Standard

This quantitative xylose standard, which is also part of our monosaccharide release and labelling kit, LT-MONO-96, is now available to order separately. The standard contains 100 nmols of xylose.

Cat # CM-XYLOSE-100

To request a quotation please contact: info@ludger.com



Ludger monosaccharide release
and labelling kit